ERBB2 and breast carcinoma: Since HER2 targeted therapy is employed throughout the course of the treatment of HER2-positive breast cancer, even in the context of relapsed disease, we interrogated the functional interaction between CDK4/6 inhibition and HER2 inhibitors.